videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

ExpreS2ion Biotech Holding

ExpreS2ion Biotechnologies is expected to release its results for the first nine months of 2025 on 13 November 2025. Later the same day at 11:00 CET, the management team will present the financial results and key achievements in a live online presentation. The presentation will be followed by a Q&A session.

You can already now sign up for the event and send in your questions. You don&#x2019;t have to participate live to submit your questions for the event. ExpreS2ion Biotechnologies is expected to release its results for the first nine months of 2025 on 13 November 2025. Later the same day at 11:00 CET, the management team will present the financial results and key achievements in a live online presentation. The presentation will be followed by a Q&amp;A session. Since the H1 2025 report, the company has announced the first early results from the ongoing Phase 1 trial of ES2B-C001, a novel immunotherapeutic vaccine candidate targeting HER2-expressing breast cancer. The data indicate that the vaccine triggers a significant immune response. Furthermore, the TO11 warrant program was completed, resulting in SEK 11.8 million in new capital before issue costs. In addition to the financial results for the first nine months, the discussion may focus on the company&#x2019;s capital position and financial runway following the completion of the warrant program, as well as an update on the development timelines for the ES2B-C001 candidate. ExpreS2ion Biotechnologies is a Danish biotechnology company focused on the development of vaccines using its proprietary ExpreS2 production platform in combination with AdaptVac&#x2019;s VLP technology. Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 13.21 CEST, 13 October 2025.

ExpreS2ion Biotechnologies - Presentation of Q3 2025 Earnings Release

Recent videos